Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential evaluation of artesunate-amodiaquine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for uncomplicated falciparum malaria in young children in the Democratic Republic of the Congo
ACTRN12616001423404Phase 4Completed
- Sponsor
- Ministry of Health
- Start
- Apr 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artesunate, amodiaquine, artemether, lumefantrine, dihydroartemisinin and 1 more in malaria and Falciparum malaria (PF) (3 arms), sponsored by Ministry of Health. Primary endpoints: Percent of treatment failures, Adequate clinical and parasitological response and 1 more. Started Apr 2017; status: completed.
02
Drugs
artesunateamodiaquineartemetherlumefantrinedihydroartemisinin
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12616001423404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001423404.